A multicenter phase II study of cabozantinib + nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902).

Presenter

Juneko E. Grilley-Olson, MD

Duke Cancer Institute, Duke University

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Videos & Slides Details

Meeting

2023 ASCO Annual Meeting

Session Type

Oral Abstract Session

Session Title

Sarcoma

Track

Sarcoma

Sub Track

Soft Tissue Tumors

Clinical Trial Registration Number

NCT04339738

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 11503)

DOI

10.1200/JCO.2023.41.16_suppl.11503

Abstract #

11503

Abstract Disclosures

FEATURED

A multicenter phase II study of cabozantinib + nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902).

Presenter

Juneko E. Grilley-Olson, MD

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Videos & Slides Details

Meeting

Session Type

Session Title

Track

Sub Track

Clinical Trial Registration Number

Citation

DOI

Abstract #

Similar Videos & Slides

Videos & Slides

Panel Question and Answer

Videos & Slides

Studying the Zebras: Rare but Not Forgotten

Videos & Slides

WJOG6110B (ELTOP): Randomized phase II trial comparing trastuzumab plus capecitabine (HX) and lapatinib plus capecitabine (LX) in HER2-positive metastatic breast cancer patients previously treated with trastuzumab and taxanes.

Videos & Slides

Randomized phase II study of capecitabine with or without ramucirumab (IMC-1121B) or IMC-18F1 in patients with unresectable, locally advanced or metastatic breast cancer (mBC) previously treated with anthracycline and taxane therapy (CP20-0903/NCT01234402).